PT3873604T - Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina - Google Patents

Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina

Info

Publication number
PT3873604T
PT3873604T PT198054397T PT19805439T PT3873604T PT 3873604 T PT3873604 T PT 3873604T PT 198054397 T PT198054397 T PT 198054397T PT 19805439 T PT19805439 T PT 19805439T PT 3873604 T PT3873604 T PT 3873604T
Authority
PT
Portugal
Prior art keywords
disease
methods
treating alzheimer
alzheimer
treating
Prior art date
Application number
PT198054397T
Other languages
English (en)
Original Assignee
Cycol Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cycol Therapeutics Inc filed Critical Cycol Therapeutics Inc
Publication of PT3873604T publication Critical patent/PT3873604T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PT198054397T 2018-10-29 2019-10-24 Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina PT3873604T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752131P 2018-10-29 2018-10-29
US201962885053P 2019-08-09 2019-08-09

Publications (1)

Publication Number Publication Date
PT3873604T true PT3873604T (pt) 2024-10-22

Family

ID=68583503

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198054397T PT3873604T (pt) 2018-10-29 2019-10-24 Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina

Country Status (10)

Country Link
US (3) US11925659B2 (pt)
EP (1) EP3873604B1 (pt)
JP (1) JP7446322B2 (pt)
KR (1) KR20210084480A (pt)
CN (1) CN112996562A (pt)
BR (1) BR112021008139A2 (pt)
CA (1) CA3114021C (pt)
ES (1) ES2992137T3 (pt)
PT (1) PT3873604T (pt)
WO (1) WO2020092107A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
WO2019056003A1 (en) 2017-09-18 2019-03-21 Eip Pharma, Llc CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745)
JP7607935B2 (ja) 2019-01-03 2025-01-06 サイクラリティ・セラピューティクス・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP4157290A4 (en) * 2020-06-02 2024-06-05 National University of Singapore COMPOSITIONS, THEIR USES IN THERAPY AND METHODS THEREFOR
WO2022051631A1 (en) 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
CN116801887A (zh) * 2020-11-06 2023-09-22 Eip制药公司 治疗神经退行性疾病的步态功能障碍
WO2022099094A1 (en) * 2020-11-06 2022-05-12 Eip Pharma, Inc. Compositions and methods for treating depression
US12285440B2 (en) 2021-03-14 2025-04-29 Massachusetts Institute Of Technology APOE4 impairs myelination via altered cholesterol biosynthesis and transport in oligodendroglia
CA3237497A1 (en) * 2021-11-18 2023-05-25 Vib Vzw Improved gamma-secretase inhibitor screening assays
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
KR102710574B1 (ko) * 2022-03-28 2024-09-27 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用
JP2025520359A (ja) * 2022-06-13 2025-07-03 ベレン セラピューティクス ピー．ビー．シー． ヒドロキシプロピル－ベータ－シクロデキストリンを製造するためのシステム及び方法
IL318600A (en) * 2022-07-29 2025-03-01 Anavex Life Sciences Corp Preparations and methods for preventing dementia caused by degenerative diseases
KR20250073473A (ko) * 2022-09-30 2025-05-27 싸이클로 테라퓨틱스, 아이엔씨. 조기 알츠하이머병 치료 방법
CN121568695A (zh) * 2024-04-12 2026-02-24 北京华昊中天生物医药股份有限公司 一种优替德隆药物组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US8883494B2 (en) 2003-11-14 2014-11-11 Adil A. KHAN In vitro model for neuronal death
KR101530050B1 (ko) 2007-03-02 2015-06-22 주식회사 노브메타파마 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법
CN104244956B (zh) 2012-04-13 2020-04-17 L&F研究有限公司 使用环糊精的方法
WO2014022841A1 (en) 2012-08-03 2014-02-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
WO2015191931A1 (en) 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
US20200000840A1 (en) * 2016-03-20 2020-01-02 Asdera Llc Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders

Also Published As

Publication number Publication date
JP2022509358A (ja) 2022-01-20
EP3873604A1 (en) 2021-09-08
KR20210084480A (ko) 2021-07-07
US20250302864A1 (en) 2025-10-02
CA3114021C (en) 2025-05-27
CA3114021A1 (en) 2021-05-07
CN112996562A (zh) 2021-06-18
US20240415871A1 (en) 2024-12-19
ES2992137T3 (es) 2024-12-09
JP7446322B2 (ja) 2024-03-08
BR112021008139A2 (pt) 2021-08-03
US11925659B2 (en) 2024-03-12
US20220008453A1 (en) 2022-01-13
WO2020092107A1 (en) 2020-05-07
EP3873604B1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
IL277498A (en) Compounds for the treatment of Huntington's disease
IL271046B1 (en) Compounds for the treatment of Huntington's disease
IL281633A (en) Methods for treating Huntington's disease
EP3645121B8 (en) Methods for treating huntington's disease
IL277333A (en) Methods for treating eye diseases
IL252433B (en) Methods for treating Alzheimer's disease
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
IL263433A (en) Methods for treating alzheimer's disease
IL277182A (en) Compositions and methods for treating Parkinson's disease
IL263188B (en) Treatment for Parkinson's disease
IL278813A (en) Gene therapy for Alzheimer's disease
PL3585373T3 (pl) Związki do stosowania w sposobach leczenia choroby Alzheimera
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
IL280326A (en) Small RNA contracts for Alzheimer's disease
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
ZA202006126B (en) Compounds for treating alzheimer's disease
GB201915753D0 (en) Alzheimer's disease
HUE047160T2 (hu) Alzheimer-kór kezelésében alkalmas tetrahidrofurán-kondenzált aminohidrotiazin-származékok
IL265656A (en) Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
EP3244897A4 (en) Methods for treating alzheimer's disease
ZA202001588B (en) Method of treating alzheimer's disease
SG11202101274XA (en) Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease
HK40041162A (en) Compounds for treating alzheimer's disease